Navigation Links
Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress
Date:8/25/2009

RIDGEFIELD, Conn., Aug. 25 /PRNewswire/ -- Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).(1)

Atrial fibrillation affects approximately 2.3 million Americans(2) and can increase the risk of stroke five-fold.(3) Top-line findings from the 18,113 patient RE-LY study(1) will be featured in an ESC press briefing on Sunday, Aug. 30 at 8:00 a.m. CEST, with the full results presented in a "Hot-Line" session at 11:00 a.m. CEST. The study will also be simultaneously published in a leading peer-reviewed medical journal.

Dabigatran etexilate is an investigational oral anticoagulant in Phase III development for stroke prevention in AF(1) and several other therapeutic areas, including prevention of atherothrombotic events in patients with acute coronary syndrome,(4) as well as primary prevention, (5),(6),(7) secondary prevention(8) and treatment of venous thromboembolism.(9) Dabigatran etexilate is not yet approved by the U.S. Food and Drug Administration.

In addition to the primary findings, a RE-LY sub-analysis of treatment naive patients will also be presented during a "Clinical Trial Update" session on Wednesday, Sept. 2 at 8:00 a.m. CEST.

About RE-LY: The largest AF outcomes trial to date

RE-LY was a global, Phase III, randomized trial of 18,113 patients(1) enrolled in more than 900 centers in 44 countries,(1) investigating whether dabigatran etexilate (two blinded doses) was as effective as well-con
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
2. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
5. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
6. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
7. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
10. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
11. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation ... of directors has approved a quarterly dividend of $0.275 (27.5 ... is payable on August 1, 2014, to holders of record ... CVS Caremark is dedicated to helping people on ... company in the United States . Through ...
Breaking Medicine Technology:
... 11 Bayer HealthCare Pharmaceuticals announced today that ... U.S. Food and Drug Administration (FDA) for ciprofloxacin dry ... to Pseudomonas aeruginosa in cystic fibrosis (CF) patients. A ... Medicines Agency. Ciprofloxacin DPI is an investigational drug–device combination ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; ... recently introduced Continuum Acetabular Cup System at the ... Continuum Cup combines the best ... Technology, Metasul ® Metal-on-Metal technology, BIOLOX ® delta ...
Cached Medicine Technology:FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 2FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 3FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 4FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 5FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 6FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 7FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 8New Hip Implant Provides Personalized Fit 2New Hip Implant Provides Personalized Fit 3New Hip Implant Provides Personalized Fit 4
(Date:7/12/2014)... 2014 Recently, Fadhits.com, a well-known wedding dress ... long graduation dresses to its product line. In ... loyal clients. It wants to bring more benefits for its ... offered at discounted prices, up to 72% off. , As ... working hard. Its online shop is a good place for ...
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... experienced steady growth over the past five years, buoyed ... the agricultural sector's supply management system. “Eggs are a ... a result, per capita egg consumption generally grows in ... IBISWorld Industry Analyst Will McKitterick. Furthermore, demand for new ...
(Date:7/12/2014)... Fresh off their respective performances in the 2014 World Cup, ... at Sun Life Stadium in an international friendly. The World ... stars in the world of football in Colombian and Brazilian ... some of the best talent in the world in early ... team in the world according to the Fédération Internationale de ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... 12, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
Breaking Medicine News(10 mins):Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5
... To be joined by special guests Ringo Starr, Sheryl Crow, ... and Jim JamesTickets go on sale Monday, March 9, at ... Paul McCartney and special guests Ringo Starr, Sheryl Crow, ... Bettye LaVette, and Jim James will perform at the David ...
... CARDIFF, Calif., March 4 Rapid Fire Marketing, (Pink ... Inc., a development stage software firm utilizing the latest ... technology works off a wireless headset that responds to ... power of your own mind. The technology has ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... of BioMarin, will present a company update at the Barclays ... 2009 at 2:30 p.m. ET. Interested parties may access ... investor section of the BioMarin website, www.BMRN.com . ...
... assistant (MCA), featuring touch screen input. The MediSlate was designed ... whether that is a hospital ward, medical clinic or emergency room. ... ... TabletKiosk ®, a leader in mobile computing solutions, today announced ...
... The Johnson Institute has transferred key programs and ... Advocacy under an agreement reached last week by ... )The transfer ensures a continuation of the Johnson ... and possibility of recovery from alcoholism and dependence ...
... will be held Saturday, October 17 at , ... Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced ... Monye Connolly, will serve as the Corporate Chair for its ... The event is scheduled in Atlanta at Centennial ...
Cached Medicine News:Health News:Paul McCartney to Headline Benefit Concert for David Lynch Foundation at Radio City Music Hall on Saturday, April 4 2Health News:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 3Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 4Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 5Health News:Johnson Institute Transfers Key Programs and Products to Hazelden Foundation 2Health News:Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes 2
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... Marker directly to the biopsy site helps ... performed. ,The MICROMARK® II Tissue Marker is ... for use with the MAMMOTOME Biopsy System. ... site after a biopsy with the MAMMOTOME ...
... A biopsy with the ... an effective, minimally invasive procedure ... patient management.,Using computer-generated images to ... more accurately pinpoint and map ...
Medicine Products: